Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682383 · ClinicalTrials.gov registry record · Phase 2
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study of Unresectable Locally Advanced NSCLC, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00682383 is a Phase 2 study of Unresectable Locally Advanced NSCLC that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00682383, a Phase 2 study of Unresectable Locally Advanced NSCLC, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
Conditions Studied
Interventions
- DRUG Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Study Locations (1)
Florida
- Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00682383
The ClinicalTrials.gov registry entry for NCT00682383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mt. Sinai Medical Center, Miami, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable Locally Advanced NSCLC appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta is the first listed.
NCT00682383 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00682383 about?
NCT00682383 is a clinical study titled "Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)". To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
What is the current status of trial NCT00682383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2003-09. Estimated completion is 2010-01.
What conditions does trial NCT00682383 study?
This clinical trial studies the following conditions: Unresectable Locally Advanced NSCLC.
What interventions are being tested in trial NCT00682383?
The interventions under investigation include: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta (DRUG).
Who is sponsoring clinical trial NCT00682383?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00682383 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.